论文部分内容阅读
目的探讨同时评价阿托伐他汀与曲美他嗪联用治疗冠心病(CHD)的临床治疗效果。方法我院在2011年6月至2012年3月共收治冠心病(CHD)患者86例,将该86例患者随机平均分为2组,即对照组和联合组各43例,2组患者均给予常规治疗(包括给予血管扩张药物、利尿剂、吸氧、钙拮抗剂、β-受体阻滞剂以及硝酸盐等);对照组患者单纯给予曲美他嗪,20mg/d,3次/d;联合组患者采用阿托伐他汀与曲美他嗪联用治疗,其中阿托伐他汀10mg/d,1次/d,曲美他嗪,20mg/d,3次/d;观察并记录对比2组患者治疗后的冠心病(CHD)患者临床症状的改善情况、临床有效率以及是否存在不良反应等。结果 :①治疗后,联合组患者在胸闷、胸痛、乏力以及心悸等等方面的临床症状改善情况明显优于对照组,2组差异具有统计学意义(P<0.05);②治疗后,联合组显效22例、有效18例、无效3例、总有效率93.0%;对照组显效18例、有效17例、无效8例、总有效率81.4%,2组患者临床有效率差异显著,具有统计学意义(P<0.05);③在治疗过程中和完成之后,2组患者均出现了不良反应,其中联合组失眠1例,呕吐1例,恶心1例,对照组失眠1例,呕吐2例,2组患者不良反应方面的差异不显著,没有统计学意义(P>0.05)。结论阿托伐他汀与曲美他嗪联用治疗冠心病拥有更加确切的临床疗效,并且不良反应与单纯采用曲美他嗪治疗差距不大,建议在临床推广使用。
Objective To evaluate the clinical efficacy of atorvastatin combined with trimetazidine in the treatment of coronary heart disease (CHD). Methods A total of 86 patients with coronary heart disease (CHD) were enrolled in our hospital from June 2011 to March 2012. The 86 patients were randomly divided into two groups, ie, 43 cases in control group and combination group, and 2 cases in both groups (Including vasodilators, diuretics, oxygen inhalation, calcium antagonists, β-blockers and nitrates, etc.); patients in the control group were given trimetazidine alone, 20 mg / d, 3 times / d; atorvastatin combined with trimetazidine in combination group was treated with atorvastatin 10mg / d, once / d, trimetazidine, 20mg / d, 3 times / d; observed and recorded The improvement of clinical symptoms, clinical efficacy and adverse reactions in patients with coronary heart disease (CHD) after treatment were compared between the two groups. Results: ① After treatment, the improvement of clinical symptoms in the combined group of patients with chest tightness, chest pain, fatigue and palpitations was significantly better than the control group, the difference between the two groups was statistically significant (P <0.05); ② After treatment, the combination group In the control group, 18 cases were markedly effective, 17 cases were effective, 8 cases were ineffective, and the total effective rate was 81.4%. There was significant difference between the two groups in the clinical effective rate, with statistical significance (P <0.05) .③At the time of treatment and after the completion of the treatment, adverse reactions occurred in both groups, including 1 case of insomnia, 1 case of vomiting, 1 case of nausea, 1 case of insomnia and 2 cases of vomiting in the control group, There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion Atorvastatin combined with trimetazidine treatment of coronary heart disease has a more precise clinical efficacy, and adverse reactions and the simple use of trimetazidine treatment is not much difference, it is recommended for clinical use.